BioVersys strengthens tuberculosis drug development with expanded GSK collaboration and CHF 12.3 million Series C boost

07.05.2024 07:01, Rita Longobardi

BioVersys, a clinical-stage company developing novel antibiotics, announced a partnership with GSK and additional funding to advance its lead tuberculosis drug candidate—alpibectir—through clinical trials.

---

---

Alpibectir, a drug candidate developed through a joint effort by BioVersys, GSK, Pasteur Institute Lille and the University of Lille, is undergoing clinical trials for treating tuberculosis (TB). This innovative drug works in a completely new way and boosts the effectiveness of an existing antibiotic, ethionamide.

The current trials focus on patients with pulmonary TB in South Africa and are showing positive signs. The encouraging results have led BioVersys and GSK to expand their collaboration. They aim to develop Alpibectir for both lung and meningeal TB, bringing this potential treatment to patients faster.

This expanded partnership includes an investment by GSK in BioVersys. This, along with additional funding from existing and new investors, brings the total raised in BioVersys' Series C financing round to CHF 44.9 million. These funds will support the further development of Alpibectir and BV100, another promising antibiotic targeting highly resistant bacteria.

BioVersys participated in Venture Leaders China in 2016, was ranked among the TOP 100 Swiss Startups from 2011 to 2013, won the final stage of Venture Kick, participated in Venture Leaders Technology in 2008 and in the SIX IPO Academy.

"As a scientific founder, the educational programs that are organized and co-organized by Venturelab, such as the SIX IPO Academy, provide very valuable toolboxes that you need during your entrepreneurial path," stated Marc Gitzinger, Co-Founder and CEO of BioVersys.

CSO Sergio Lociuro, CEO Marc Gitzinger, and Chief Development Officer Glenn Dale